SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
To explore the beneficial effects of 'empagliflozin + ARB' in comparison with 'placebo + ARB'
on the reduction of nocturnal blood pressure in T2DM with hypertension